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ABSTRACT 
Quantitative structure–activity relationship (QSAR) and Molecular modeling study have been performed on a series of novel 
Pazopanib derivatives by using the Mixed Hansch Fujita-Ban approach and employing AM1 calculations in docking study which 
give insight into the structural requirements of the derivatives towards inhibitory activity against VEGFR-2, PDGFR-α and c-kit 
tyrosine kinases enzymes. Evaluation of the predictive ability of the resulting models is carried out by using ‘Leave-one-out’ (LOO) 
method of cross validation. There is a remarkable agreement in the results of both the approaches. From the QSAR study it can be 
inferred that methyl substitution at 5th position of the terminal benzene ring and hydrophobicity play a key role in kinase inhibitory 
activity. Potential binding sites were elucidated by docking study. Docking simulations was performed through Molegro Virtual 
Docker (MVD) for lead optimization of compound as protein tyrosine kinase inhibitors. 
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INTRODUCTION: 
Cancer is the second leading cause of death in the 
western world. Despite advances in diagnosis and 
treatment, overall survival of patients still remains poor. 
This has improved survival in several types of solid 
tumors, but treatment-related toxicity and emergence of 
drug resistance have been the major cause of morbidity 
and mortality. Hence, there is an urgent need to develop 
newer more effective therapy to improve patient 
outcomes 
1
.  
Tyrosine kinases (TKs) represent a major subclass of 
protein kinases, which play a pivotal role for 
intracellular signal transduction. Crucial cellular 
processes are regulated by TK signaling, such as 
adhesion, proliferation, migration, invasion, 
differentiation, metabolism, angiogenesis, survival and 
apoptotic cell death 
2
. Tyrosine kinase is an enzyme that 
transfers a phosphate group from ATP to a tyrosine 
residue on specific cellular proteins. Many growth 
factors such as insulin, epidermal growth factor, and 
platelet-derived growth factor mediate their effects via 
receptor, switches on the kinase activity of catalytic 
domain. This signaling cascade is altered in cancer cell, 
which cause over expression of TK receptors. TKs 
generally activate downstream target proteins through 
phosphorylation or provide binding sites for protein–
protein interactions
 3
. Pazopanib (Votrient, GW786034) 
is a novel multi-targeted receptor tyrosine kinase 
inhibitor, having both anti-proliferative  and anti-
angiogenic properties, targeting the vascular endothelial 
growth factor receptor (VEGFR-1, -2 and -3), platelet-
derived growth factor receptor (PDGFR-α and -β), and 
c-kit. It was first approved by Food Drug Administration 
(FDA) as an agent to treat metastatic renal cell 
carcinoma in 2009, and again approved by FDA in 2012 
to treat soft tissue sarcoma. Clinical experience with 
Pazopanib demonstrates the advantages of broad-
spectrum anticancer potency and less prone to 
resistance
4
.
 
 
The aim of this study is to explore the structural 
requirements of pazopanib derivatives for inhibiting the 
tyrosine kinase enzyme activity by employing two – 
dimensional (2D) QSAR approach. Further docking 
study has been performed on this series by using 
Molegro Virtual Docker (MVD) 1.2 software. This study 
gives the idea for rational design of tyrosine kinase 
inhibitors which will exhibit greater therapeutic efficacy 
and safety. 
MATERIALS AND METHODS: 
Data Set and Molecular Modeling  
Thirteen compounds were taken for the QSAR and 
docking study as tyrosine kinase inhibitors from the 
previously reported literature
5
. The biological activity 
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data (IC50 in nM) was converted into negative 
logarithmic dose (-logIC50 or pIC50 in mole) to reduce 
the skewness of data taken as dependent variable, which 
exhibit the correlation with independent variable or 
descriptors listed in (table 1). 
  pIC50 = -log10 IC50                                                                      (1) 
Where, IC50 is the nano molar concentration of the 
kinase inhibitors producing 50% inhibition. Initially 
series was subjected to QSAR analysis via De Novo 
contribution of substituent to the activity of molecule by 
employing Mixed Hansch Fujita-Ban approach. Here 
physicochemical descriptors and indicator variables 
which are used in Hansch-FB analysis. Molecular 
modeling study was carried out via Chem Office Ultra 
Version 8.0(Cambridge Soft.Corp.), Molegro virtual 
Docker (MVD) 1.2
 
and regression analysis study was 
done by using VALSTAT software. Sequential Multiple 
Linear regression (SMLR) analysis was used to generate 
the QSAR model. Validation is a crucial step in any 
QSAR modeling method.  It is needed to establish the 
predictiveness of a model on unseen data and it helps to 
determine the complexity of an equation that the amount 
of data justifies. Model is validated both internally (least 
square fit R
2
, Leave-one out-cross validation or q
2, γ 
randomization, boots-trapping r
2
bs) and externally 
(predictive ability of correlation coefficient r
2
pred). 
N
N
N
NN N
CH3
R1
CH3H
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Table 1: Common Structure and Inhibitory activity data (IC50) of pazopanib analogs as anticancer agents 
S.No. Compd R1 R2 IC50(nM)  pIC50(M)  
    
VEGF
R-2 
PDGFR-α 
C-
Kit 
VEGFR-2 PDGFR-α C-Kit 
1 7a CH3 3-F 78 130 102 7.108 6.886 6.991 
2 7b CH3 3-Br 64 97 98 7.194 7.013 7.009 
3 7c CH3 3-Cl 25   85 80 7.602 7.071 7.097 
4 7d CH3 3OCH3 38 96 72 7.420 7.018 7.143 
5 7 CH3 3-CH3 42 80 87 7.377 7.097 7.060 
6 7f CH3 3,5-DiMethyl 21 52 40 7.678 7.284 7.398 
7 7g CH3 4-SCH3 51 94 71 7.292 7.027 7.149 
8 7h CH3 4-OCF3 72 104 89 7.143 6.983 7.051 
9 7i H 3-F 93 140 96 7.032 6.854 7.018 
10 7j H 3-Cl 72 95 72 7.143 7.022 7.143 
11 7k H 3-OCH3 108 86 77 6.967 7.066 7.114 
12 7l H 4-OCF3 12 72 83 7.921 7.143 7.081 
13 7m H 3,5-DiMethyl 28 75 61 7.553 7.125 7.215 
 
The docking study was performed to observe the 
interaction of all compounds with the receptor and to 
examine the agreement between the docking pattern and 
predictive activity of the validated pharmacophore. The 
docking study was carried out on tyrosine kinase 
enzyme using Molegro virtual docker (MVD) 1.2 
software  by 64 bit operating system under window 8 
with an Intel ®Celeron® Processor N2840. Reported 
crystal structure of tyrosine kinase enzyme inhibitor was 
extracted from the Protein Data Bank (PDB Id: 1t46) 
(http://www.rcsb.org/pdb). Before docking, protein is 
prepared by using Protein preparation wizard, where 
water molecule and cofactors are removed from the 
proteins, optimizing the hydrogen bonds and deleting 
the ligands present in the crystal structure. For docking, 
ligand structures were prepared using Cambridge 
software and were subjected to energy minimization. 
The active site was generated using grid box. The lowest 
energy conformation was selected where RMS gradient 
reaches to 0.01kcal/mol and RMS distance to 0.1A
o
 and 
were also subjected to energy minimization. 
RESULTS AND DISCUSSION: 
Generation of QSAR Model for Hansch-Fujita ban 
approach 
Model-1 (for VEGFR-2 receptor) 
BA= [7.527(± 0.247)] +HA [0.469( ± 0.691)] +ℛ 
[1.131( ± 1.089)] 
Contribution of parameters to model is     
HA:ℛ::1:6.168………………(1) 
n=13, r=0.600, r
2
=0.360, r
2
adj=0.232, std=0.248, 
F=2.814 
Model-2 (for PDGFR-α receptor)  
BA= [7.036( ± 0.084)] +MR [0.019( ± 0.015)] - ℱ 
[0.388( ± 0.217)] 
Contribution of parameters to model is     
MR:ℱ::1.128:1………………(2) 
n=13, r=0.818, r
2
=0.669, r
2
adj=0.603, std=0.069, 
F=10.117, FIT=1.190, 
Bivariant equations were generated for both VEGFR 
and PDGFR-α receptor, which mediate tyrosine-kinase 
inhibitiory activity. In model 1, difference between r
2
adj 
and r
2
 is less than 0.3, which indicates that model is 
significant. Internal validity of the model is observed via 
q
2
 or cross validated correlation-coefficient. Model also 
express SPRESS and SDEP activity. Model 1 suggested that 
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hydrogen acceptor group should be present in the 
designed molecule, which contribute positively and 
favored towards the inhibition. Whereas in model 2, MR 
contribute positively and field effect contribute 
negatively to the activity, which suggests that less bulky 
group is optimum for the activity. 
 
Figure 1: Plot between observed vs calculated and predicted activity of model-1,2,3 
 
Model-3 (for c-Kit receptor) 
BA= [7.071(± 0.047)] +R4SMe [0.078( ± 0.156)] +R5C 
[0.236( ± 0.115)] 
Contribution of parameters to model is           
R4S:R5C::1:6.022……………(3) 
n=13, r=0.827, r
2
=0.685, r
2
adj=0.622, STD=0.066, 
F=10.860 
This model gives the idea about the substitution at 4 and 
5 position in designing the analogues for c-kit receptor. 
According to the model, at 4
th
 position thiomethyl 
substitution and 5
th 
position methyl group should be 
present there for its inhibitory activity.  
  
Table 2: Observed, calculated and predicted IC50 (by the LOO method) via Hansch-Fujita ban approach of pazopanib  
analogs as anticancer agents 
Hansch-Fujita- ban analysis 
VEGFR-2  (Model-1) PDGFR-α   (Model-2)                 c-Kit  (Model-3) 
Compd. Obs. Calc. Pred.(Loo) Compd. Obs. Calc. Pred.(Loo) Compd. Obs. Calc. Pred.(Loo) 
1 7.108 7.143 7.151 1 6.886 6.886 6.886 1 6.991 7.071 7.080 
2 7.194 7.335 7.348 2 7.013 7.033 7.042 2 7.009 7.071 7.078 
3 7.602 7.358 7.335 3 7.071 6.990 6.974 3 7.097 7.071 7.068 
4 7.420 7.420 - 4 7.018 7.084 7.098 4 7.143 7.071 7.063 
5 7.377 7.380 7.381 5 7.097 7.157 7.172 5 7.060 7.071 7.072 
6 7.678 7.380 7.351 6 7.284 7.157 7.123 6 7.398 7.307 7.215 
7 7.292 7.527 7.584 7 7.027 7.055 7.063 7 7.149 7.149 - 
8 7.143 7.527    7.619 8 6.983 7.055 7.076 8 7.051 7.071 7.073 
9 7.032 7.143 7.169 9 6.854 6.886 6.904 9 7.018 7.071 7.077 
10 7.143 7.358 7.378 10 7.022 6.991 6.984 10 7.143 7.071 7.063 
11 6.967 6.951 6.933 11 7.066 7.084 7.088 11 7.114 7.071 7.066 
12 7.921 7.527 7.433 12 7.143 7.055 7.030 12 7.081 7.071 7.070 
13 7.553 7.380 7.363 13 7.125 7.157 7.165 13 7.215 7.307 7.398 
 
Docking Studies 
Docking study was performed to gain structural insight 
into the binding mode of most active compound. This 
study was carried out via Molegro Virtual Docker 
program on (Pdb Id: 1t46) (fig.2).as tyrosine kinase 
inhibitors. The best binding model of compound 7f is 
shown in (fig.3). In the binding model, compound 7f 
was nicely bound with ATP binding site of kinase 
inhibitor receptors through hydrophobic, H-bonding and 
steric interactions. Docking score of compound 7f was 
found to be -151.594, indicates high binding affinity and 
better H-Bonding interactions with protein (1t46) 
residues. From the figure, it was revealed that 
compound 7f was nicely bound to Asp 810A amino-acid 
residues by two hydrogen bonds. Among them, One H-
bond is formed between amino (-NH-) group of 
Pyrimdine ring and amino –acid residue of Asp810A. 
Whereas another –NH- group between phenyl and 
pyrimidine ing also takes part in H-bonding interaction. 
Data of kinase inhibition study suggested that, H-
bonding interaction plays an important role in its 
inhibitory activity. Rather than H-bonding interaction, 
compound 7f also exhibited hydrophobic and steric 
interaction with Glu640, Val668, Val654 and Leu644 
amino-acid residues. 
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Figure 2 (a) : 3D crystal structure 
of  tyrosine kinase inhibitors pdb 
code:1t46 
Figure 2(b): 2D view of 
receptor and their interactions is 
Shown.    
Figure 3: Molegro predicted binding mode 
of the ligand 7f is shown. Blue colour 
indicates hydrogen bonding interactions, and 
red colour shows steric interaction. 
CONCLUSION:   
In this paper, QSAR and docking study was performed 
on a series of pazopanib derivatives as anticancer 
agents, where inhibitory activity was observed against 
VEGFR-2, PDGFR-α and c-Kit tyrosine-kinase enzyme. 
QSAR models were developed by using Sequential 
multiple linear regression analysis. Mixed Hansch 
Fujita-Ban approach suggested that R2 substituent in 
pazopanib ring is more favorable for kinase inhibition 
and lipophilicity also plays crucial role towards its 
inhibitory activity. Data also suggested that more polar 
and less bulky group contribute positively at R2 
position, whereas R1 position is unsubstituted or 
substituted by smaller group play an important role to its 
inhibitory activity. Docking study revealed that H-bond 
interaction plays significant role in the kinase inhibition 
activity. On the basis of docking analysis, compound 7f 
was found most potent compound as tyrosine-kinase 
inhibitors. 
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